{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:27:54Z","timestamp":1773800874932,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The use of umbilical cord-derived mesenchymal stem cells as HDT for COVID-19 has been shown to be safe in phase 1 and 2 trials. Trials of anti-interleukin-6 receptor antibodies show promising mortality benefit in hospitalized COVID-19 patients. Repurposed drugs and monoclonal antibodies targeting specific cytokines acting on different aspects of the pro- and anti-inflammatory cascades are under evaluation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>A range of HDTs shows promise for reducing mortality and improving long term disability in patients with severe COVID-19, and require evaluation in randomized, controlled trials<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcp.0000000000000769","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T01:52:55Z","timestamp":1614390775000},"page":"205-209","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Host-directed therapies for COVID-19"],"prefix":"10.1097","volume":"27","author":[{"given":"Markus","family":"Maeurer","sequence":"first","affiliation":[{"name":"ImmunoSurgery Unit, Champalimaud Centre for the Unknown, Lisbon, Portugal"},{"name":"I Medizinische Klinik, Johannes Gutenberg University Mainz, Germany"}]},{"given":"Renata","family":"Ramalho","sequence":"additional","affiliation":[{"name":"Egas Moniz Higher Education School, Instituto Universit\u00e1rio Egas Moniz, Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz (CiiEM, U4585-FCT), Applied Nutrition Studies Group (G.E.N.A.-IUEM), Monte de Caparica, Portugal"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China"}]},{"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[{"name":"Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK"}]}],"member":"276","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China Lancet"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-020-17240-2","article-title":"Immunological and inflammatory profiles in mild and severe cases of COVID-19","volume":"11","author":"Song","year":"2020","journal-title":"Nat Commun"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mri.2020.11.004","article-title":"High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19","volume":"76","author":"Heiss","year":"2021","journal-title":"Magn Reson Imaging"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S0140-6736(20)30305-6","article-title":"Reducing mortality from 2019-nCoV: host-directed therapies should be an option","volume":"395","author":"Zumla","year":"2020","journal-title":"Lancet"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijid.2020.05.040","article-title":"Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of mesenchymal stromal (stem) cell (MSC) therapy \u2212 achieving global consensus and visibility for cellular host-directed therapies","volume":"96","author":"Zumla","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R10-20250730","doi-asserted-by":"crossref","DOI":"10.1007\/s11684-020-0810-9","article-title":"Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19","author":"Tang","year":"2020","journal-title":"Front Med"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomised, double-blind, placebo controlled phase 2 trial","volume":"6","author":"Shi","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13063-020-04964-1","article-title":"Double-blind, randomized, controlled, trial to assess the efficacy of allogeneic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): a structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Payares-Herrera","year":"2021","journal-title":"Trials"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s13063-020-04416-w","article-title":"Repair of acute respiratory distress syndrome by stromal cell administration in COVID-19 (REALIST-COVID-19): a structured summary of a study protocol for a randomised, controlled trial","volume":"21","author":"Gorman","year":"2020","journal-title":"Trials"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"e23582","DOI":"10.1097\/MD.0000000000023582","article-title":"Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience","volume":"100","author":"Castelnovo","year":"2021","journal-title":"Medicine"},{"key":"R16-20250730","first-page":"e0327","article-title":"Tocilizumab in coronavirus disease 2019-related critical illness: a propensity matched analysis","volume":"3","author":"Rajendram","year":"2021","journal-title":"Crit Care Explor"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15\u200adays in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijid.2020.07.016","article-title":"Mortality in COVID-19 disease patients: correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants","volume":"98","author":"de Sousa","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Current Opinion in Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCP.0000000000000769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:00:53Z","timestamp":1753912853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCP.0000000000000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mcp.0000000000000769","relation":{},"ISSN":["1070-5287","1531-6971"],"issn-type":[{"value":"1070-5287","type":"print"},{"value":"1531-6971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]}}}